(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 169.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.47%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Mesoblast's revenue in 2026 is $17,198,000.On average, 6 Wall Street analysts forecast MESO's revenue for 2026 to be $148,936,981,879, with the lowest MESO revenue forecast at $127,694,646,444, and the highest MESO revenue forecast at $188,155,176,489. On average, 7 Wall Street analysts forecast MESO's revenue for 2027 to be $210,221,810,793, with the lowest MESO revenue forecast at $128,764,699,012, and the highest MESO revenue forecast at $288,952,592,465.
In 2028, MESO is forecast to generate $469,594,361,567 in revenue, with the lowest revenue forecast at $225,325,423,599 and the highest revenue forecast at $741,472,191,757.